• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非选择性β受体阻滞剂可能会使肝硬化患者的门静脉系统血栓形成加重:一项回顾性观察研究。

Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study.

机构信息

Department of Gastroenterology, General Hospital of Northern Theater Command (Formerly General Hospital of Shenyang Military Area), Shenyang, China.

Postgraduate College, Shenyang Pharmaceutical University, Shenyang, China.

出版信息

Adv Ther. 2020 Apr;37(4):1452-1463. doi: 10.1007/s12325-020-01250-z. Epub 2020 Feb 19.

DOI:10.1007/s12325-020-01250-z
PMID:32076942
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7140745/
Abstract

INTRODUCTION

Occlusive portal venous system thrombosis (PVT) is significantly associated with poor outcomes in cirrhotic patients. Nonselective β-blockers (NSBBs) may be associated with the development of PVT. However, the role of NSBBs in progressing thrombosis remains unclear.

METHODS

Forty-three patients on whom contrast-enhanced computed tomography or magnetic resonance imaging was performed twice, and for whom there was detailed information regarding NSBBs, were eligible in this study, including 16 in the NSBBs group and 27 in the no NSBBs group. A composite endpoint of progressing thrombosis included the development of PVT in patients without PVT and aggravation of PVT in patients with PVT. Logistic regression analysis was employed to identify the effect of NSBBs on the progression of PVT.

RESULTS

At the last admission, 13 patients had progressing thrombosis. The incidence of progressing thrombosis was significantly higher in the NSBBs group than in the no NSBBs group [50.0% (8/16) vs. 18.5% (5/27), P = 0.030]. The use of NSBBs (odds ratio 4.400, 95% confidence interval 1.107-17.482, P = 0.035) was significantly associated with progressing thrombosis in univariate logistic regression analyses, but not significant (odds ratio 4.084, 95% confidence interval 0.488-34.158, P = 0.194) in multivariate logistic regression analyses.

CONCLUSIONS

NSBBs may play a role in the progression of PVT in liver cirrhosis. The benefits and risks of NSBBs in the management of liver cirrhosis should be fully weighed.

摘要

简介

在肝硬化患者中,闭塞性门静脉系统血栓形成(PVT)与不良预后显著相关。非选择性β受体阻滞剂(NSBBs)可能与 PVT 的发展有关。然而,NSBBs 在促进血栓形成方面的作用尚不清楚。

方法

这项研究纳入了 43 名接受过两次对比增强计算机断层扫描或磁共振成像检查且有详细 NSBB 使用信息的患者,包括 16 名 NSBB 组患者和 27 名无 NSBB 组患者。进展性血栓形成的复合终点包括无 PVT 患者发生 PVT 和有 PVT 患者 PVT 加重。采用 logistic 回归分析确定 NSBBs 对 PVT 进展的影响。

结果

在最后一次入院时,13 名患者发生进展性血栓形成。NSBB 组进展性血栓形成的发生率明显高于无 NSBB 组[50.0%(8/16)比 18.5%(5/27),P=0.030]。在单变量 logistic 回归分析中,使用 NSBBs(比值比 4.400,95%置信区间 1.107-17.482,P=0.035)与进展性血栓形成显著相关,但在多变量 logistic 回归分析中无统计学意义(比值比 4.084,95%置信区间 0.488-34.158,P=0.194)。

结论

NSBBs 可能在肝硬化患者 PVT 的进展中起作用。在肝硬化的管理中,应充分权衡 NSBBs 的利弊。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ac4/7140745/74042365a429/12325_2020_1250_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ac4/7140745/05010c503cf0/12325_2020_1250_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ac4/7140745/f8c879ac2940/12325_2020_1250_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ac4/7140745/74042365a429/12325_2020_1250_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ac4/7140745/05010c503cf0/12325_2020_1250_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ac4/7140745/f8c879ac2940/12325_2020_1250_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ac4/7140745/74042365a429/12325_2020_1250_Fig3_HTML.jpg

相似文献

1
Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study.非选择性β受体阻滞剂可能会使肝硬化患者的门静脉系统血栓形成加重:一项回顾性观察研究。
Adv Ther. 2020 Apr;37(4):1452-1463. doi: 10.1007/s12325-020-01250-z. Epub 2020 Feb 19.
2
Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis.非选择性β受体阻滞剂可能会诱发肝硬化患者门静脉血栓形成。
World J Gastroenterol. 2014 Aug 28;20(32):11463-6. doi: 10.3748/wjg.v20.i32.11463.
3
Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.非选择性β受体阻滞剂与肝硬化门静脉血栓形成的相关性:系统评价和荟萃分析。
Hepatol Int. 2019 Jul;13(4):468-481. doi: 10.1007/s12072-019-09951-6. Epub 2019 Jun 7.
4
The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients.在肝硬化患者中,使用非选择性β受体阻滞剂是门静脉血栓形成的一个危险因素。
Saudi J Gastroenterol. 2018 Jan-Feb;24(1):25-29. doi: 10.4103/sjg.SJG_100_17.
5
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.非选择性β受体阻滞剂会增加肝硬化合并自发性细菌性腹膜炎患者发生肝肾综合征和死亡的风险。
Gastroenterology. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005. Epub 2014 Mar 12.
6
Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of β-Blockers.非肿瘤性门静脉血栓形成在肝硬化中的作用:β-受体阻滞剂的可能作用。
Med Princ Pract. 2018;27(5):466-471. doi: 10.1159/000492893. Epub 2018 Aug 14.
7
Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis.肝硬化门静脉血栓形成的流行病学:系统评价和荟萃分析。
Eur J Intern Med. 2022 Oct;104:21-32. doi: 10.1016/j.ejim.2022.05.032. Epub 2022 Jun 7.
8
Neutrophil extracellular traps formation may be involved in the association of propranolol with the development of portal vein thrombosis.中性粒细胞胞外诱捕网形成可能与普萘洛尔引起门静脉血栓形成有关。
Thromb Res. 2024 Jun;238:208-221. doi: 10.1016/j.thromres.2024.04.030. Epub 2024 May 1.
9
Risk factors associated with portal vein thrombosis in liver cirrhosis: A case-control study.肝硬化门静脉血栓形成的相关危险因素:一项病例对照研究。
Ter Arkh. 2019 Mar 18;91(2):73-81. doi: 10.26442/00403660.2019.02.000153.
10
Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort.全国代表性住院患者队列中肝硬化门静脉血栓形成的患病率及其相关死亡率。
J Gastroenterol Hepatol. 2019 Jun;34(6):1088-1092. doi: 10.1111/jgh.14501. Epub 2018 Nov 4.

引用本文的文献

1
Portal Vein Variations, Clinical Correlation, and Embryological Explanation: A Review Article.门静脉变异、临床关联及胚胎学解释:一篇综述文章
Cureus. 2023 Mar 20;15(3):e36400. doi: 10.7759/cureus.36400. eCollection 2023 Mar.
2
Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review.肝硬化背景下的门静脉血栓形成:全面综述
J Clin Med. 2022 Oct 30;11(21):6435. doi: 10.3390/jcm11216435.
3
Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding.

本文引用的文献

1
Use of nonselective β blockers after variceal eradication in cirrhotic patients undergoing secondary prophylaxis of esophageal variceal bleeding: a critical review of current evidence.肝硬化患者在食管静脉曲张出血二级预防中进行静脉曲张根除后使用非选择性β受体阻滞剂:对当前证据的批判性综述
Ther Adv Chronic Dis. 2019 Jul 12;10:2040622319862693. doi: 10.1177/2040622319862693. eCollection 2019.
2
Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.非选择性β受体阻滞剂与肝硬化门静脉血栓形成的相关性:系统评价和荟萃分析。
Hepatol Int. 2019 Jul;13(4):468-481. doi: 10.1007/s12072-019-09951-6. Epub 2019 Jun 7.
3
骨髓增殖性肿瘤相关门静脉高压的特征及静脉曲张出血的内镜治疗
Ther Adv Chronic Dis. 2022 Sep 22;13:20406223221125691. doi: 10.1177/20406223221125691. eCollection 2022.
4
Increase in Free Hepatic Venous Pressure Response to Beta-Blockers Predicts Variceal Bleeding in Cirrhotic Patients.β受体阻滞剂增加肝静脉自由压反应可预测肝硬化患者静脉曲张出血。
Biomed Res Int. 2021 Apr 26;2021:5587566. doi: 10.1155/2021/5587566. eCollection 2021.
5
No Association of Homocysteine, Anticardiolipin Antibody, and Anti-β2 Glycoprotein I Antibody With Portal Venous System Thrombosis in Liver Cirrhosis.同型半胱氨酸、抗心磷脂抗体和抗β2糖蛋白 I 抗体与肝硬化门静脉系统血栓形成无关。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211010969. doi: 10.1177/10760296211010969.
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.
急性肝衰竭合并慢性肝病:亚太肝病学会(APASL)的共识推荐意见:更新版。
Hepatol Int. 2019 Jul;13(4):353-390. doi: 10.1007/s12072-019-09946-3. Epub 2019 Jun 6.
4
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.β 受体阻滞剂预防有临床显著门静脉高压症的肝硬化失代偿(PREDESCI):一项随机、双盲、安慰剂对照、多中心试验。
Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22.
5
Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study.非选择性β受体阻滞剂与肝硬化患者门静脉血栓形成风险:一项前瞻性纵向研究的结果。
Aliment Pharmacol Ther. 2019 Mar;49(5):582-588. doi: 10.1111/apt.15137. Epub 2019 Jan 22.
6
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis.肝硬化门静脉血栓形成抗凝治疗的临床影响和安全性。
Am J Gastroenterol. 2019 Feb;114(2):258-266. doi: 10.1038/s41395-018-0421-0.
7
Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort.全国代表性住院患者队列中肝硬化门静脉血栓形成的患病率及其相关死亡率。
J Gastroenterol Hepatol. 2019 Jun;34(6):1088-1092. doi: 10.1111/jgh.14501. Epub 2018 Nov 4.
8
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.欧洲肝脏研究学会失代偿期肝硬化患者管理临床实践指南
J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10.
9
Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study.门静脉速度降低可预测门静脉血栓形成的发生:一项配对病例对照研究。
Liver Int. 2018 Jan;38(1):94-101. doi: 10.1111/liv.13500. Epub 2017 Sep 9.
10
Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis.肝硬化合并门静脉血栓形成患者抗凝治疗的效果:系统评价和荟萃分析。
Gastroenterology. 2017 Aug;153(2):480-487.e1. doi: 10.1053/j.gastro.2017.04.042. Epub 2017 May 4.